EMA Says CHMP Has Recommended Granting A Marketing Authorisation In European Union For Rasonque (Daraxonrasib) For Metastatic Pancreatic Cancer
https://www.ema.europa.eu/en/news/ema-recommends-authorisation-rasonque-metastatic-pancreatic-cancer
Share
Why It Matters
A European health group approved a new pancreatic cancer medicine. This shows the company's drug works and can now be sold in Europe.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.